Running discussion on SP

GTG Target SP 1.2c -

Our CEO attended a US 4day industry function last week.
Hopefully while he's in the US..!
He's staying over to sign-up the 3 new key hire's..

1)
We are now waiting on 3 key US hires they are in the middle of recruiting, said by CEO in early May.

(3)key US hires in order to accelerate the Genetype program:
1. Chief medical officer - well progressing.
2. Chief US based marketing officer.
3. Very senior commercial person US based.

We await a formal announcement from the Co. on these important and strategic US based key hires.
Expecting news this week or the next.


2)
We're hoping the GTG/GENE board has told their CEO to stay in the States until he closes the DEALs on at least 2 Payer sign-ups before his return..

:Q3 webinar 4th MAY23.
We think that over the next zero to three months that we will probably be embarking on commercial pilots with one or two payers..


3)
Genetype Commercialization - 9 key tests now available for sale in the US..
- 6 or more Peer reviewed publications published in the last 6mths supporting the science, validity & performance behind the Genetype tests.


4)
Aug-Sep? - Launch of the HBOC comprehensive test.
Expect slippage..

:Q3 webinar 4th MAY23.
shared in February this year was the development of a new comprehensive breast and ovarian cancer test.
This is a world's first.
There is no single test out there that looks at the monogenic disease, polygenic and clinical risk model which looks at everyone who is at risk of breast cancer. As many of you would know, BRCA only accounts for about 5% of diagnosed cancers. The other 10% is from familial and 85% where the traditional Genetype brand focuses on is from polygenic, sporadic or random disease.

So we've got a test now that is under development at the moment and is being prepared for launch which will focus on all of those three elements and it will be the most Comprehensive Hereditary Breast and Ovarian Cancer test on the market. all said by the CEO.


All imo.
GLAH.
.